{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:34:50Z","timestamp":1768264490050,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00520-018-4594-2","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T11:27:20Z","timestamp":1545132440000},"page":"793-803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions"],"prefix":"10.1007","volume":"27","author":[{"name":"On behalf of Rome Transplant Network","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3858-1635","authenticated-orcid":false,"given":"Andrea","family":"Tendas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mengarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ombretta","family":"Annibali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Tomarchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debora","family":"Saltarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Chierichini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirko","family":"Di Venanzio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Sollazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Piedimonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Cupelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gottardo","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Delbono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Niscola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio Pio","family":"Perrotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"de Fabritiis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Arcese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"issue":"8","key":"4594_CR1","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1007\/s00520-015-2711-z","volume":"23","author":"A Tendas","year":"2015","unstructured":"Tendas A, Niscola P, Perrotti A, Dentamaro T, de Fabritiis P, Arcese W, Rome Transplant Network (RTN) Quality of Life Working Party (2015) Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need. Support Care Cancer 23(8):2211. https:\/\/doi.org\/10.1007\/s00520-015-2711-z","journal-title":"Support Care Cancer"},{"issue":"5","key":"4594_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00520-012-1411-1","volume":"20","author":"A Tendas","year":"2012","unstructured":"Tendas A, Sollazzo F, Bruno A, Cupelli L, Niscola P, Pignatelli AC, Dentamaro T, de Fabritiis P, Arcese W (2012) Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant. Support Care Cancer 20(5):891\u2013892. https:\/\/doi.org\/10.1007\/s00520-012-1411-1","journal-title":"Support Care Cancer"},{"issue":"2","key":"4594_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10561-011-9248-2","volume":"13","author":"MA Cox","year":"2012","unstructured":"Cox MA, Kastrup J, Hrubi\u0161ko M (2012) Historical perspectives and the future of adverse reactions associated with haemopoietic stem cells cryopreserved with dimethyl sulfoxide. Cell Tissue Bank 13(2):203\u2013215","journal-title":"Cell Tissue Bank"},{"key":"4594_CR4","unstructured":"NCCN guidelines NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Antiemesis. Version 3.2018; https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf . Accessed 15 Jan 2018"},{"key":"4594_CR5","unstructured":"Oncology Nursing Society ONS. Emetogenic Risk Of Chemotherapy and Biotherapy Agents. https:\/\/www.ons.org\/sites\/default\/files\/emetogenicity_tool.pdf . Accessed 15 Jan 2018"},{"issue":"3","key":"4594_CR6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1634\/theoncologist.4-3-191","volume":"4","author":"PJ Hesketh","year":"1999","unstructured":"Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4(3):191\u2013196","journal-title":"Oncologist"},{"issue":"1","key":"4594_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/bmt.2009.114","volume":"45","author":"M Musso","year":"2010","unstructured":"Musso M, Scalone R, Crescimanno A, Bonanno V, Polizzi V, Porretto F, Bianchini C, Perrone T (2010) Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 45(1):123\u2013127. https:\/\/doi.org\/10.1038\/bmt.2009.114","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 5","key":"4594_CR8","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, On behalf of the participants of the MASCC\/ESMO Consensus Conference Copenhagen 2015 et al (2016) MASCC and ESMO Consensus Guidelines for the Prevention of Chemotherapy and Radiotherapy-Induced Nausea and Vomiting: ESMO Clinical Practice Guidelines. Ann Oncol 27(suppl 5):v119\u2013v133","journal-title":"Ann Oncol"},{"issue":"1","key":"4594_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00520-016-3313-0","volume":"25","author":"J Herrstedt","year":"2017","unstructured":"Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, Chan A, Aapro MS (2017) 2016 Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer 25(1):277\u2013288","journal-title":"Support Care Cancer"},{"issue":"1","key":"4594_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bbmt.2012.08.003","volume":"19","author":"MH Abidi","year":"2013","unstructured":"Abidi MH, Agarwal R, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Ratanatharathorn V, Zonder J, Uberti J (2013) A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function. Biol Blood Marrow Transplant 19(1):56\u201361. https:\/\/doi.org\/10.1016\/j.bbmt.2012.08.003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"4594_CR11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/annonc\/mdq457","volume":"22","author":"SA Giralt","year":"2011","unstructured":"Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW (2011) Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol 22(4):939\u2013946. https:\/\/doi.org\/10.1093\/annonc\/mdq457","journal-title":"Ann Oncol"},{"issue":"6","key":"4594_CR12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/bmt.2010.205","volume":"46","author":"K Jordan","year":"2011","unstructured":"Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll HJ (2011) The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant 46(6):784\u2013789. https:\/\/doi.org\/10.1038\/bmt.2010.205","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"4594_CR13","first-page":"00085","volume":"4","author":"AMG Marquez","year":"2017","unstructured":"Marquez AMG, Vazquez LC, Fernandez CAS, Moral JLS (2017) Revision of nausea and vomiting in patients with haematological malignancies and hematopoietic transplantation. Hematol Transfus Int J 4(3):00085","journal-title":"Hematol Transfus Int J"},{"issue":"9","key":"4594_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.clml.2017.06.012","volume":"17","author":"S Trifilio","year":"2017","unstructured":"Trifilio S, Welles C, Seeger K, Mehta S, Fishman M, McGowan K, Strejcek K, Eiten E, Pirotte C, Lucier E, DeFrates S, Mehta J (2017) Olanzapine reduces chemotherapy-induced nausea and vomiting compared with aprepitant in myeloma patients receiving high-dose melphalan before stem cell transplantation: a retrospective study. Clin Lymphoma Myeloma Leuk 17(9):584\u2013589","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"4594_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/1078155213502103","volume":"20","author":"D Deauna-Limayo","year":"2014","unstructured":"Deauna-Limayo D, Aljitawi OS, Ganguly S, Abhyankar S, Wick JA, McGuirk JP (2014) Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: a pilot study. J Oncol Pharm Pract 20(4):263\u2013269. https:\/\/doi.org\/10.1177\/1078155213502103","journal-title":"J Oncol Pharm Pract"},{"issue":"11","key":"4594_CR16","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1007\/s00520-014-2248-6","volume":"22","author":"T Bechtel","year":"2014","unstructured":"Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr, Jaglowski S, Penza S, Andritsos LA, Devine SM (2014) Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. Support Care Cancer 22(11):2911\u20132916. https:\/\/doi.org\/10.1007\/s00520-014-2248-6","journal-title":"Support Care Cancer"},{"issue":"30","key":"4594_CR17","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1200\/JCO.2013.55.0095","volume":"32","author":"T Schmitt","year":"2014","unstructured":"Schmitt T, Goldschmidt H, Neben K, Freiberger A, H\u00fcsing J, Gronkowski M, Thalheimer M, Pelzl le H, Mikus G, Burhenne J, Ho AD, Egerer G (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32(30):3413\u20133420. https:\/\/doi.org\/10.1200\/JCO.2013.55.0095","journal-title":"J Clin Oncol"},{"issue":"3","key":"4594_CR18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1177\/1078155215585190","volume":"22","author":"SM Clark","year":"2016","unstructured":"Clark SM, Clemmons AB, Schaack L, Garren J, DeRemer DL, Kota VK (2016) Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. J Oncol Pharm Pract 22(3):416\u2013422. https:\/\/doi.org\/10.1177\/1078155215585190","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"4594_CR19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1248\/bpb.b12-01012","volume":"36","author":"M Uchida","year":"2013","unstructured":"Uchida M, Ikesue H, Miyamoto T, Kato K, Suetsugu K, Ichinose K, Hiraiwa H, Sakurai A, Takenaka K, Muta T, Iwasaki H, Teshima T, Shiratsuchi M, Egashira N, Akashi K, Oishi R (2013) Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation. Biol Pharm Bull 36(5):819\u2013824","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"4594_CR20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12185-016-2152-6","volume":"105","author":"A Isoda","year":"2017","unstructured":"Isoda A, Saito R, Komatsu F, Negishi Y, Oosawa N, Ishikawa T, Miyazawa Y, Matsumoto M, Sawamura M, Manaka A (2017) Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: a phase II study. Int J Hematol 105(4):478\u2013484. https:\/\/doi.org\/10.1007\/s12185-016-2152-6","journal-title":"Int J Hematol"},{"issue":"5","key":"4594_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1634\/theoncologist.7-5-424","volume":"7","author":"S Goodin","year":"2002","unstructured":"Goodin S, Cunningham R (2002) 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist 7(5):424\u2013436","journal-title":"Oncologist"},{"issue":"9","key":"4594_CR22","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1345\/aph.1C510","volume":"37","author":"RM Navari","year":"2003","unstructured":"Navari RM, Koeller JM (2003) Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother 37(9):1276\u20131286","journal-title":"Ann Pharmacother"},{"key":"4594_CR23","unstructured":"Zofran Label \u2013 FDA. U.S Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020103s035_020605s019_020781s019lbl.pdf . Accessed 15 Jan 2018"},{"issue":"7","key":"4594_CR24","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00520-011-1226-5","volume":"20","author":"G Gonullu","year":"2012","unstructured":"Gonullu G, Demircan S, Demirag MK, Erdem D, Yucel I (2012) Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 20(7):1435\u20131439. https:\/\/doi.org\/10.1007\/s00520-011-1226-5","journal-title":"Support Care Cancer"},{"key":"4594_CR25","unstructured":"Emend Label \u2013 FDA. U.S Food and Drug Administration website. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021549s016lbl.pdf . Accessed 15 Jan 2018"},{"issue":"4","key":"4594_CR26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00520-009-0680-9","volume":"18","author":"BL Rapoport","year":"2010","unstructured":"Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423\u2013431. https:\/\/doi.org\/10.1093\/annonc\/mdq149 Review","journal-title":"Support Care Cancer"},{"issue":"8","key":"4594_CR27","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1177\/0091270003256113","volume":"43","author":"M Feuring","year":"2003","unstructured":"Feuring M, Lee Y, Orlowski LH, Michiels N, De Smet M, Majumdar AK, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hesney M, Brackett LE, Wehling M (2003) Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. J Clin Pharmacol 43(8):912\u2013917","journal-title":"J Clin Pharmacol"},{"key":"4594_CR28","unstructured":"Multidrug interaction checker \u2013 Medscape Reference. http:\/\/reference.medscape.com\/drug-interactionchecker . Accessed 15 Jan 2018"},{"key":"4594_CR29","unstructured":"Drug interaction - WebMD. http:\/\/www.webmd.com\/interaction-checker\/ . Accessed 15 Jan 2018"},{"key":"4594_CR30","unstructured":"Drug interactions checker \u2013 For drugs, foods and alcohol \u2013 Drugs.com . https:\/\/www.drugs.com\/drug_interactions.html . Accessed 15 Jan 2018"},{"issue":"12","key":"4594_CR31","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1093\/annonc\/mdq149","volume":"21","author":"MS Aapro","year":"2010","unstructured":"Aapro MS, Walko CM (2010) Aprepitant: drug-drug interactions in perspective. Ann Oncol 21(12):2316\u20132323","journal-title":"Ann Oncol"},{"issue":"2","key":"4594_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/annonc\/mdl347","volume":"18","author":"SM Grunberg","year":"2007","unstructured":"Grunberg SM (2007) Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol 18(2):233\u2013240","journal-title":"Ann Oncol"},{"key":"4594_CR33","unstructured":"Decadron \u2013 FDA. U.S Food and Drug Administration website. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/11664slr062_decadron_lbl.pdf . Accessed 15 Jan 2018"},{"issue":"1","key":"4594_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/JOE-07-0606","volume":"197","author":"O Schakman","year":"2008","unstructured":"Schakman O, Gilson H, Thissen JP (2008) Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 197(1):1\u201310. https:\/\/doi.org\/10.1677\/JOE-07-0606","journal-title":"J Endocrinol"},{"key":"4594_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1164\/ajrccm.150.1.8025735","volume":"150","author":"M Decramer","year":"1994","unstructured":"Decramer M, Lacquet LM, Fagard R, Rogiers P (1994) Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 150:11\u201316","journal-title":"Am J Respir Crit Care Med"},{"key":"4594_CR36","doi-asserted-by":"publisher","unstructured":"Fardet L, Petersen I, Nazareth I (2016) Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med 13(5):e1002024. https:\/\/doi.org\/10.1371\/journal.pmed.1002024","DOI":"10.1371\/journal.pmed.1002024"},{"issue":"9","key":"4594_CR37","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1002\/cncr.11320","volume":"97","author":"SP Chawla","year":"2003","unstructured":"Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97(9):2290\u20132300","journal-title":"Cancer"},{"key":"4594_CR38","unstructured":"Zyprexa Label \u2013 FDA. U.S Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020592s051,021086s030,021253s036lbl.pdf . Accessed 15 Jan 2018"},{"key":"4594_CR39","doi-asserted-by":"publisher","unstructured":"Tendas A, Marchesi F, Annibali O, Saltarelli D, Niscola P, Perrotti AP, Arcese W (2018) Chemotherapy induced nausea and vomiting prophylaxis in high-dose melphalan and autologous stem cell transplantation. Clin Lymphoma Myeloma Leuk Article in Press. https:\/\/doi.org\/10.1016\/j.clml.2017.12.001","DOI":"10.1016\/j.clml.2017.12.001"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4594-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4594-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4594-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T03:16:21Z","timestamp":1605669381000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4594-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["4594"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4594-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"assertion":[{"value":"10 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}